Revenue: As of FY2026 Q1, the actual value is USD 20.75 M, beating the estimate of USD 13.34 M.EPS: As of FY2026 Q1, the actual value is USD -1.69, beating the estimate of USD -1.8034.EBIT: As of FY2026 Q1, the actual value is USD -110.03 M.<h4>Segment Revenue</h4><ul><li>Total Product Revenue, Net: Agios Pharmaceuticals, Inc. reported $20,746 thousand for the three months ended March 31, 2026, marking an increase of $12,020 thousand from $8,726 thousand for the same period in 2025. This growth was attributed to higher U.S. product revenue and the introduction of rest of world product revenue .<ul><li>United States: Product revenue, net, in the U.S. was $18,851 thousand for the three months ended March 31, 2026, an increase from $8,726 thousand in the prior year period. This was primarily due to increased volume from AQVESME™, launched in December 2025, and PYRUKYND® .</li><li>Rest of World: Product revenue, net, from the rest of the world was $1,895 thousand for the three months ended March 31, 2026, compared to no revenue in the same period of 2025, mainly due to increased volume associated with the NewBridge Agreement .</li></ul></li></ul><h4>Operational Metrics</h4><ul><li>Cost of Sales: Increased to $1,319 thousand for the three months ended March 31, 2026, from $1,085 thousand for the same period in 2025 .</li><li>Research and Development (R&amp;D) Expenses: Total R&amp;D expenses increased by $8,405 thousand, rising from $72,743 thousand in Q1 2025 to $81,148 thousand in Q1 2026. This was driven by a $4,700 thousand increase in indirect, workforce-related expenses and a $3,700 thousand increase in direct expenses, primarily for PYRUKYND®/AQVESME™ process development costs .<ul><li>PK activator (PYRUKYND®/AQVESME™) direct expenses: - $23,905 thousand in Q1 2026, compared to - $21,321 thousand in Q1 2025 .</li><li>Compensation and related R&amp;D expenses: - $36,789 thousand in Q1 2026, compared to - $32,990 thousand in Q1 2025 .</li><li>Novel PK activator (tebapivat): - $5,925 thousand in Q1 2026, compared to - $5,388 thousand in Q1 2025 .</li><li>PAH stabilizer (AG-181): - $968 thousand in Q1 2026, compared to - $382 thousand in Q1 2025 .</li><li>siRNA targeting TMPRSS6 (AG-236): - $1,708 thousand in Q1 2026, compared to - $1,496 thousand in Q1 2025 .</li></ul></li><li>Selling, General and Administrative (SG&amp;A) Expenses: Increased by $6,777 thousand, from $41,527 thousand in Q1 2025 to $48,304 thousand in Q1 2026, due to commercial activities for the AQVESME™ launch and higher stock compensation expense .</li><li>Total Operating Expenses: Increased to $130,771 thousand in Q1 2026 from $115,355 thousand in Q1 2025 .</li><li>Loss from Operations: - $110,025 thousand for Q1 2026, compared to - $106,629 thousand for Q1 2025 .</li><li>Interest Income, Net: Decreased to $10,795 thousand in Q1 2026 from $16,087 thousand in Q1 2025, primarily due to a lower investment balance .</li><li>Other Income, Net: $119 thousand in Q1 2026, compared to $1,253 thousand in Q1 2025 .</li><li>Net Loss: Increased to - $99,111 thousand in Q1 2026 from - $89,289 thousand in Q1 2025, primarily due to increased R&amp;D and SG&amp;A expenses and decreased interest income, partially offset by increased product revenue .</li><li>Accumulated Deficit: - $660,816 thousand as of March 31, 2026 .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: - $118,920 thousand for the three months ended March 31, 2026, compared to - $111,489 thousand for the same period in 2025, primarily due to operating expenses, partially offset by product revenues and interest income .</li><li>Net Cash Provided by Investing Activities: $141,312 thousand for the three months ended March 31, 2026, compared to $112,587 thousand for the same period in 2025, mainly from higher proceeds from maturities and sales of marketable securities than purchases .</li><li>Net Cash Provided by Financing Activities: $2,078 thousand for the three months ended March 31, 2026, compared to $1,619 thousand for the same period in 2025, primarily from stock option exercises and employee stock purchase plan proceeds .</li><li>Cash and Cash Equivalents at End of Period: $113,600 thousand as of March 31, 2026 .</li></ul><h4>Unique Metrics</h4><ul><li>Cash, Cash Equivalents and Marketable Securities: Agios Pharmaceuticals, Inc. held $1.0 billion as of March 31, 2026 .</li><li>Stock-based Compensation Expense: Total stock-based compensation expense was $15,541 thousand in Q1 2026, with $5,695 thousand allocated to R&amp;D and $9,846 thousand to SG&amp;A .</li></ul><h4>Future Outlook and Strategy</h4>Agios Pharmaceuticals, Inc. anticipates that its current cash, cash equivalents, and marketable securities, combined with projected product revenue and interest income, will ensure financial independence for the U.S. commercial launch of AQVESME™ and the potential U.S. launch of mitapivat in SCD. The company plans to advance its existing clinical programs and strategically expand its pipeline through both internal and external asset discovery. Future capital needs are contingent on factors such as product sales revenue, potential royalty payments from Retained Earn-Out Rights, commercialization and R&amp;D costs, and the ability to establish collaborations .

Agios Pharmac | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 20.75 M